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Abstract
Objective—Pro-inflammatory cytokines have been implicated in the pathophysiology and 
maintenance of depression. This study investigated the effects of a brief mindfulness intervention 
on salivary pro-inflammatory correlates of depression (IL-6, TNF-α) and self-reported symptoms 
of depression in college women.
Methods—Sixty-four females with a cut score of ≥ 16 on the Center for Epidemiological Studies 
for Depression Scale (CES-D) were assigned to a 4-week mindfulness-based intervention (MBI; 
N=31) or a contact-control group (N=33). For both groups, salivary cytokines and depressive 
symptoms were assessed at baseline and post-treatment. For the mindfulness group only, salivary 
cytokines were also assessed at a 3-month follow-up.
Results—Both groups showed similar reductions in depression. However, MBI (vs. control) 
predicted greater reductions in IL-6 and TNF-α; changes in IL-6 were sustained at 3-month 
follow-up. Higher baseline depressive symptoms predicted greater reductions in inflammation in 
the mindfulness group.
Conclusion—MBIs may reduce inflammatory immune markers commonly implicated in 
depression. Individuals with greater depressive symptoms may benefit more from mindfulness 
training. Although reductions in salivary cytokines in the mindfulness condition were not 
attributable to changes in depressive symptoms, future work should examine the possibility that 
such reductions are protective against the development of future depressive episodes.
Public Health Significance—Pro-inflammatory cytokines, which have been implicated in the 
pathophysiology of depression, may be reduced following brief mindfulness training among 
healthy young women with depressive symptomatology, particularly for those with higher baseline 
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symptoms. These findings may highlight an important treatment target for reducing risk of 
depressive disorders via mindfulness-based interventions.
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Depression is a common and serious psychiatric disorder associated with negative 
psychosocial and physical outcomes (American Psychiatric Association, 2013; Evans et al., 
2005). A majority of adults meeting criteria for major depression experienced symptom 
onset in childhood, adolescence, or young adulthood (Kessler, Chiu, Demler, Merikangas, & 
Walters, 2005); even mild depressive symptoms in adolescence predict heightened risk for 
major depression and suicide later in life (Fergusson, Horwood, Ridder, & Beautrais, 2005). 
Prevention efforts in women may be particularly important, since women in the United 
States are 70% more likely than men to experience lifetime depression (Kessler et al., 2003). 
Therefore, reduction of major depression and suicide risk requires the development of 
prevention and intervention strategies targeting early depressive symptoms in female 
children, adolescents, and young adults.
Dysregulation of inflammatory immune responses, which are implicated in the 
pathophysiology and maintenance of depression, represents a promising target for the 
prevention of depression. Immune profiles characterized by elevated pro-inflammatory 
cytokines (e.g., interleukin-6 or IL-6, tumor necrosis factor α or TNF-α) promote “sickness 
behavior”, a set of vegetative, somatic, and psychological responses that mimic depression 
(Dantzer, O'Connor, Freund, Johnson, & Kelley, 2008; Raison, Capuron, & Miller, 2006). In 
line with this evidence, low-grade baseline inflammation has been shown to prospectively 
predict onset and persistence of depression across the lifespan (Zalli, Jovanova, Hoogendijk, 
Tiemeier, & Carvalho, 2015; Wichers et al., 2006). Sickness behaviors such as social 
withdrawal and psychomotor slowing are thought to have evolved to conserve and redirect 
energy to the immune system in order to effectively fight infection. In spite of this 
evolutionary hypothesis, the link between pro-inflammatory cytokines and depressive 
behaviors appears bidirectional; inflammation promotes depressive behavior, and depressive 
behavior enhances inflammation (Dantzer, 2012; Howren, Lamkin, & Suls, 2009). A recent 
meta-analysis suggests that these associations are particularly robust for IL-6 and TNF-α 
(Dowlati et al., 2010). Therefore, prevention and intervention programs that target 
psychosocial, behavioral, and immunological characteristics of depression may be 
particularly promising.
Mindfulness based interventions (MBIs) have demonstrated the capacity to improve both 
psychosocial and immunological aspects of depression. Mindfulness training promotes 
nonjudgmental, non-attached awareness of experiences in the present moment (Baer, 2003). 
Cultivation of such states enhances attentional regulation, disengagement from rumination, 
and tolerance of aversive experiences (Baer, 2003). MBIs have gained empirical support for 
the treatment of diverse disorders (Keng, Smoski, & Robins, 2011), including reduced 
symptoms in acutely depressed individuals and the prevention of depressive relapse among 
those at-risk (Chiesa & Serretti, 2011; Strauss, Cavanagh, Oliver, & Pettman, 2014). 
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Additionally, several studies show that MBIs reduce depression and other psychological 
symptoms among children, adolescents, and young adults (Caldwell, Harrison, Adams, 
Quin, & Greeson; Deckro et al., 2002; Greeson, Juberg, Maytan, James, & Rogers, 2014; 
Semple, Lee, Rosa, & Miller, 2010). Finally, recent evidence suggests that MBIs may be of 
particular benefit to individuals with greater baseline depressive symptom severity (Arch & 
Ayers, 2013; Greeson et al., 2015). Though mechanisms of this association are still being 
actively investigated, it is hypothesized that MBIs promote the development of skills that 
target cognitive-emotional processes relevant to chronic or severe depression (e.g., 
rumination), which may mitigate the physiological stress reactivity that promotes chronic 
inflammation (e.g., Creswell & Lindsay, 2014).
In addition to their psychosocial effects, MBIs have been shown to alter pro-inflammatory 
immune profiles, including reduced inflammatory cytokines and c-reactive protein (Carlson, 
Speca, Faris, & Patel, 2007; Carlson, Speca, Patel, & Goodey, 2003; Malarkey, Jarjoura, & 
Klatt, 2013; Witek-Janusek et al., 2008) and down-regulated expression of inflammation-
related genes (Creswell et al., 2012). However, existing studies have largely examined 
populations with chronic disease (e.g., cancer), making it difficult to assess whether changes 
in immune function are a result of improvement in illness, psychological health, or both. 
Therefore, it is unknown whether findings are generalizable to younger and otherwise 
healthy individuals with depressive symptoms. Finally, many studies have failed to include 
control conditions or investigate the long-term benefits of MBIs on inflammatory function.
The current study evaluated whether a brief MBI reduces pro-inflammatory salivary 
cytokines in young women with depressive symptomatology. Healthy women with mild to 
moderate self-reported depressive symptoms were assigned to either the MBI or a contact-
control condition. Participants completed three assessments: (a) before treatment initiation 
(baseline), (b) immediately following treatment (6-weeks post-MBI), and (c) 3 months after 
treatment (MBI only). Depressive symptoms and cytokines (IL-6, TNF-α) were assessed at 
each timepoint. There were three hypotheses:
1) Participation in a brief MBI, compared to contact-control condition, would 
reduce both depressive symptoms and inflammation at immediate post-
intervention assessment, and that these changes would be sustained at a 3-
month follow-up in the mindfulness group.
2) Given recent evidence suggesting that greater baseline depression severity 
predicts a stronger beneficial effect of MBIs on psychological symptoms (e.g., 
Greeson et al., 2015), we predicted that individuals with greater baseline 
depressive symptoms would show greater reductions in self-reported 
depression and inflammation (controlling for one's baseline levels of 
depression and inflammation).
3) The impact of mindfulness training on inflammation would be mediated by 
changes in depressive symptoms.
Walsh et al. Page 3
J Consult Clin Psychol. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Methods
CONSORT Guidelines
Information on participant flow is presented in the Results section (based on consolidated 
standards of reporting trials [CONSORT] recommendations) and can be viewed in Figure 1.
Participant Recruitment and Allocation
Screening Process—Students in introductory psychology courses were pre-screened for 
depressive symptoms using the Center for Epidemiological Depression Scale (CES-D; 
Radloff, 1977). Women endorsing mild to moderate depressive symptoms (scores ranging 
from 16-24) were invited to complete a phone screening. Eligibility criteria included: (a) 
endorsement of depressive symptoms based upon the CES-D, (b) ages 18-25 years, (c) 
female, (d) absence of active suicidal ideation, (d) absence of specific psychiatric 
disturbance (i.e., psychosis, mania, PTSD, substance dependence), (e) absence of immune 
disease or disorder, (f) absence of pregnancy, (g) not currently taking psychotropic agents, 
statins, beta-blockers, anti-hypertensives, and nonsteroidal anti-inflammatory drugs, (h) 
willingness to be randomly assigned to either mindfulness or contact-control condition, and 
(i) fluency in English.
Group Assignment—Due to scheduling constraints (e.g., course conflicts), unrestricted 
randomization for all participants was not possible. Therefore, group allocation procedures 
were as follows: a) If a participant could participate in any of the available group times, she 
was randomized to a group; b) If a participant could only participate in a restricted number 
of groups, she was randomized to a group that fit within her schedule; and c) If a participant 
could only participate in one group, she was assigned to that particular group. To further 
minimize selection bias, the PI and participants were blind to condition until all eligible 
participants were enrolled. After enrollment was complete, condition (i.e., mindfulness 
training or contact-control) was randomized for each group. Participants learned their 
condition status at the baseline visit. Groups (N=8), ranging from 5-16 participants, took 
place in the early mornings (8am or 9am). The same master's level clinical psychologist 
served as group leader for both conditions. Participants provided informed consent and 
procedures were approved by the Institutional Review Board. Multilevel models revealed 
negligible intraclass correlations (ICCs) between group membership and outcomes within 
both the MBI condition and contact-control condition (ICCs < .05); therefore, outcome data 
were treated as independent rather than group-nested.
Study Procedures
Baseline Assessment—Participants received an overview of the study and completed 
self-report measures and a saliva sample for assessment of cytokines. Participants were 
asked to abstain from caffeine, nicotine, exercise, and alcohol/drugs at least 12 hours prior to 
the session.
Mindfulness Training Sessions—Mindfulness training sessions were completed in 
weeks 2-5 following baseline assessment. Participants met in groups with the group leader 
once per week to practice a specific mindfulness exercise. Each session included 35 minutes 
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of mindfulness practice and 15 minutes discussion (e.g., discussion of weekly experience, 
applicability of practice to daily life). Digital recordings of each mindfulness practice and 
tracking logs were given to participants to monitor home practice. However, due to the low 
frequency of at-home practice during the study, this variable was not included in any 
analyses.
• Body Scan (Week 2): The group leader led participants in an exercise 
asking them to non-judgmentally observe their body. Emphasis was placed 
on examining the sensations present in each location. Practice is described 
in Segal, Williams, & Teasdale (2012).
• Sitting Meditation (Weeks 3 & 5): The group leader led participants 
through an exercise asking them to non-judgmentally observe: 1) the 
sensations of breathing, 2) the sensations present in the body, 3) the 
content of thoughts, 4) the presence of emotions, and 5) the sounds in the 
environment. Practice is described in Segal et al. (2012). Because sitting 
meditation receives considerable attention in MBIs, two sessions were 
devoted to this exercise.
• Yoga (Week 4): The group leader led participants through light stretching 
exercises described in Kabat-Zinn (1990). Participants were asked to focus 
nonjudgmentally on the particular sensations associated with bodily 
movement.
Contact-control Sessions—During weeks 2-5, participants met in groups with the 
group leader for 50 minutes once per week to complete questionnaires unrelated to the study.
Post-treatment Assessment—Participants completed assessment measures equivalent 
to those collected during the baseline session. At this assessment, participants in the contact-
control groups were invited to take part in a brief mindfulness course the following semester.
3-month Follow-up Assessment (mindfulness training ONLY)—Participants met 
with the group leader in small groups or individually to complete self-report and salivary 
assessments. These sessions were held approximately three months following completion of 
the post-treatment assessment and lasted 45 minutes. Twenty-one participants attended this 
session and provided complete follow-up data. An additional three participants who moved 
out of state completed self-report questionnaires only and returned by mail within two weeks 
of receipt.
Individuals in the contact-control group were not evaluated at the 3-month follow-up. Based 
upon IRB requirements, participants in the contact-control group were offered the described 
mindfulness intervention immediately following the post-treatment assessment. Because we 
could not predict whether participants would engage in treatment at the start of the following 
semester, and thereby confound results, we chose not to assess them at this time point.
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Compensation—Participants received course credit and up to $60 for participation. All 
participants received course credit and $20 for participation, and a $20 bonus for completing 
all sessions. MBI participants received an additional $20 for the 3-month follow-up visit.
Psychological Measures
Depressive Symptoms—The Center for Epidemiologic Depression Scale (CES-D) is a 
widely used 20-item inventory of depressive symptoms (Radloff, 1977). A score of 16 or 
higher is extensively used as a cut point for significant depressive symptoms (Radloff, 
1977). For the current study, scores ranging from 16-24 were used to screen for mild to 
moderate symptoms of depression (Greden & Schwenk, 1997). The CES-D was also 
administered at baseline and follow-up assessments to monitor changes in depression 
severity. CES-D items were scored such that higher total scores were indicative of greater 
depressive symptoms. Internal consistencies were as follows: Baseline (α = .80), post-
treatment (α = .79), 3-month follow-up (α = .65).
Structured Clinical Interview for DSM-IV-TR Axis-I Disorders (SCID-I)—The 
SCID-I is a semi-structured interview used to diagnose the major Axis I DSM-IV-TR 
disorders (First, Spitzer, Gibbon, & Williams, 1997). During phone screening, the following 
modules were used to exclude participants based on the presence of particular psychiatric 
features or disorders: active suicidality, Substance Use Disorders (current or within one 
year), Post-Traumatic Stress Disorder (current), and lifetime history of mania and/or 
psychosis.
Biological Measures
Salivary cytokine samples—IL-6 and TNF-α were measured in whole unstimulated 
saliva (e.g., Ebersole et al., 2013; Izawa, Miki, Liu, & Ogawa, 2013; Pezelj-Ribaric et al., 
2004). Saliva was collected via passive drool method. Participants were asked to abstain 
from caffeine, tobacco, alcohol, illicit drugs, and exercise for 12 hours prior to saliva sample 
collection. To collect saliva, participants rinsed their mouths with bottled water for 30 
seconds, waited 10 minutes, then filled a tube with 2-5ml of their saliva (Sarstedt AG & 
CO). Saliva was initially stored for 1-4 weeks at −25°C before being transferred to −80°C 
before assay.
Immunoassays were performed according to established protocols for salivary measurement 
of IL-6 and TNF-α (e.g., Ebersole et al., 2013). Salivary concentrations of IL-6 and TNF-α 
were measured according to manufacturer specifications using the High Sensitivity Human 
Cytokine Millipore™ MILLIPLEX® MAP kit (Millipore, Billerica, MA). Assays were 
performed in duplicate to maximize reliability. Intra- and inter-assay coefficients of variance 
were within respective specifications (IL-6: 3.51% and 4.48%; TNF-α: 3.49% and 3.78%).
Potential Covariates
General health questionnaire—Demographic information (age, race/ethnicity, marital 
status, grade, religious affiliation), history of psychotherapy and mindfulness practice were 
collected at the baseline assessment. At all assessments, participants reported on health-
related information: height and weight (to calculate BMI); health history (e.g., current 
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illness, allergies); oral health (e.g., gingivitis, mouth sores); medications (e.g., hormonal 
contraception use); menstrual cycle day; caffeine, alcohol, and drug use; sleep; and physical 
activity. These variables were assessed as potential controls in cytokine analyses. The only a 
priori covariate was hormonal contraception use. For the remaining variables, only those that 
significantly correlated with salivary cytokines were included as covariates in analyses (see 
Segerstrom, 2009).
Data Screening
None of our dependent variables met the assumption of normality (i.e., the skewness for a 
given dependent variable was more than three times the standard error of its skewness). In 
the case of the CES-D, a linear square root transformation resulted in a normal distribution. 
IL-6 and TNF-α, however, could not be corrected to normality using linear transformations. 
Further inspection of the cytokine variables suggested that they could be best characterized 
by either an overdispersed Poisson or negative binomial distribution; comparison of model 
fit for regressions described in the following paragraph revealed that an overdispersed 
Poisson regression provided the best model fit when examining cytokine outcomes (Gardner, 
Mulvey, & Shaw, 1995). Between-person covariates (e.g., BMI) were grand-mean centered 
for use as predictors.
Statistical Analyses
Because some visits were missing at random in the 6-week follow-up (1 participant in 
Contact Control, 1 participant in MBI) and at 3-month follow-up in the MBI condition (7 
participants), missing values were imputed using multiple imputation in SAS PROC MI. To 
test the prediction that mindfulness training would predict greater reductions in depressive 
symptoms, regression models were fit in SAS PROC REG with baseline depressive 
symptoms in step 1, and condition (MBI = 1, Contact-control = 0) in step 2. To test the 
prediction that mindfulness training would predict greater reductions in cytokines, 
overdispersed Poisson regression models were fit in SAS PROC GENMOD with baseline 
levels of the relevant cytokine in step 1, and condition in step 2 (Gardner et al., 1995). 
Where significant effects of condition were not found, paired sample t-tests (standard paired 
samples t-tests for depression, Wilcoxon signed-rank tests for cytokines) were carried out to 
determine if the outcome variable changed pre-post intervention in the whole sample. All 
analyses were carried out in 20 datasets imputed using SAS PROC MI; results were 
combined using SAS PROC MIANALYZE.
To test the prediction that improvements in cytokine levels and depressive symptoms would 
remain significant at 3-month follow-up for those in the mindfulness intervention, paired 
samples t-tests (standard paired samples t-tests for depressive symptoms, Wilcoxon signed-
rank tests for cytokines) tested for differences between baseline and 3-month follow-up 
within the mindfulness condition. Finally, we also tested the hypothesis that baseline 
depressive symptoms as measured using the CES-D Total Score would moderate the impact 
of condition on treatment outcomes at time 2 by testing overdispersed Poisson regression 
models predicting time 2 outcomes from baseline depressive symptoms, baseline levels of 
the outcome, condition, and the interaction of condition and baseline depressive symptoms.
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Results
Participant Flow
Figure 1 provides information on accrual and retention of study participants. Out of 1,169 
female students screened, 292 met the cut score criterion for mild to moderate depressive 
symptoms (~25% of the pool) and were invited to participate in the study. 79 students were 
assessed for eligibility, of which 64 met eligibility criteria and were assigned to a 
mindfulness training group (n=31) or a contact-control group (n=33). At the post-treatment 
assessment, 62 participants completed the study (MBI=30; contact-control=32). Twenty-four 
participants in the mindfulness group completed the 3-month follow-up assessment 
(retention=77%). Participants who completed the 3-month follow-up were similar to those 
who did not complete this visit with respect to baseline depressive symptoms and 
demographic variables (all p's > .10).
Baseline Data
Demographic information by group can be found in Table 1. There were no significant 
differences in age, race/ethnicity, current grade, or religious affiliation between the two 
conditions (age: t(62) = −.18, p = .86; race: X2(2) = 2.19, p = .33, current grade: X2(2) = 
1.44, p = .49, religious affiliation: X2(2) = 1.24, p = .74). No significant associations were 
found between demographic variables and baseline IL-6 or TNF-α. Descriptives for 
outcome variables at baseline and post-treatment for the full sample and by condition can be 
found in Table 2.
Treatment Effects
Condition Effects on Salivary Cytokines and Depression—Hormonal 
contraceptive (HC) use was controlled for a priori. Upon inspection of correlations between 
IL-6, TNF-α, and variables measured in the general health questionnaire, only one 
significant correlation emerged: baseline BMI was correlated with TNF-α at baseline (r(60) 
= .25, p < .0001) and at post-treatment (r(59) = .35, p < .0001). Of note, correlations 
between BMI and IL-6 measures were not significant at baseline (r(60) = .21, p = .19) or at 
post-treatment (r(60) = .15, p = .20). Therefore, HC use was controlled in the model 
predicting IL-6, and both HC use and BMI (standardized) were controlled for in the model 
predicting TNF-α.
Controlling for baseline IL-6, mindfulness training predicted lower IL-6 at post-treatment 
(BCONDITION = −.57, SE = .16, 95% CI: −.91 to −.25, p = .0006; ExpB = .54, 95% CI: .38 
to .75); see Figure 2). Likewise, controlling for baseline TNF-α, mindfulness training 
predicted lower TNF-α post-treatment (BCONDITION = −.52, SE = .21, 95% CI: −.94 to −.
10, p = .013; ExpB = .69, 95% CI: .49 to .96; see Figure 2). In contrast, controlling for 
baseline depression, participation in mindfulness training did not predict depression at post-
treatment (CES-D: BCONDITION = 1.06, SE = 1.22, 95% CI: .67 to 1.56, p = .39). However, 
depression decreased from baseline to post-treatment regardless of condition (CES-D: Mean 
Difference: −3.10, 95% CI = −4.59 to −1.61, t = − 4.08, p < .0001; standardized B = −.16; 
95% CI: −.08 to −.23)1.
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Longitudinal Outcomes within the Mindfulness Training Condition—Additional 
within-group analyses tested whether changes within the mindfulness condition were 
significant from pre- to post-treatment and whether they persisted at 3-month follow-up. 
Within the mindfulness condition, IL-6 decreased significantly from baseline at both post-
treatment and 3-month follow-up (Mean Difference from baseline to post-treatment = −.58, 
95% CI = −.27 to −.98; z = −45.6, p = .012 ; d = −.38; Mean Difference from baseline to 3-
month follow-up = −.75, 95% CI = −.45 to −1.87, t = −1.98, p = .045; d = −.29; z = −48.5, p 
= .022; d = −.29). Although TNF-α decreased significantly from baseline to post-treatment, 
the decrease from baseline to the 3-month follow-up assessment was not significant (Mean 
Difference from baseline to post-treatment = −.53, 95% CI = −1.05 to −.41, z = −49.3, p = .
01; d = −.49; Mean Difference from baseline to 3-month follow-up = −.45, 95% CI = −1.48 
to .72, z = −39.2, p = .10; d = −.25). CES-D decreased significantly from baseline to post-
treatment (Mean Difference from baseline to post-treatment = 2−2.71, 95% CI = −3.46 to 
−1.83, t = −2.35, p = .018; d = −.48) and from baseline to the 3-month follow-up (Mean 
Difference from baseline to 3-month follow-up = −2.76, 95% CI = −5.19 to −.32, t = −2.25, 
p = .026; d = −.45).
Baseline Depression as a Moderator of Condition Effects on Depression and Inflammation
Next, we tested the hypothesis that those with higher depressive symptoms at time 1 (i.e., 
higher scores on the CES-D) would benefit more from mindfulness training; see Table 3 for 
model information. Contrary to prediction, the interaction of baseline CES-D and condition 
did not predict post-treatment depressive symptoms over and above baseline scores 
(BCONDITION*BLDEP = 1.34, SE = 1.31, 95% CI: −1.81 to 2.34, p = .16). Consistent with 
predictions, baseline depressive symptoms interacted with condition to predict post-
treatment IL-6 (standardized BCONDITION*BLDEP = −.42, SE = .16, 95% CI: −.73 to −.10, p 
= .009; see Figure 3). At 1 standard deviation above the mean of baseline CES-D, 
mindfulness training predicted lower IL-6 at post-treatment controlling for baseline 
(BCONDITION = −.95, SE = .26, 95% CI: −1.48 to −.58, p < .0001; ExpB = .37, 95% CI: .21 
to .64); however, condition had no effect at 1 standard deviation below the mean of baseline 
CES-D (BCONDITION = −.06, SE = .36, 95% CI: -.78 to .61, p = .95).
The result for TNF-α was similar: the model predicting post-treatment TNF-α controlling 
for baseline revealed an interaction of baseline depressive symptoms and condition 
(BCONDITION*BLDEP = −.44, SE = .21, 95% CI: −.85 to −.026, p = .037; see Figure 3). 
Again, the effect of mindfulness training was significant at 1 standard deviation above the 
mean of baseline CES-D (BCONDITION = −1.04, SE = .38, 95% CI: −1.81 to −.31, p = .005; 
ExpB = .31, 95% CI: .20 to .51), but was not significant at 1 standard deviation below the 
mean of baseline CES-D (BCONDITION = .03, SE = .48, 95% CI: −.76 to .83, p = .85). Thus, 
women with higher baseline depressive symptoms who participated in mindfulness training 
did not benefit more than their less depressed counterparts in terms of self-reported 
depression; however, they did appear to show greater reductions in pro-inflammatory 
salivary cytokines.
1Because there were no effects of mindfulness training on depression, hypothesized meditational models were not considered. 
However, several post-hoc analyses ruled out mediation by changes in health-related variables such as oral health, physical activity, 
and caffeine or alcohol consumption (all p's > .85).
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Discussion
Summary and Integration with Existing Evidence
The present study examined whether a brief mindfulness-based intervention (MBI) could 
reduce self-reported depression and associated salivary inflammatory markers in young 
women with depressive symptomatology. As predicted, mindfulness training predicted 
greater reductions in pro-inflammatory immune correlates of depression (IL-6, TNF-α) than 
a contact control group pre- to post-assessment. In the mindfulness condition, reductions in 
IL-6 were sustained at a 3-month follow-up assessment. Contrary to the prediction, however, 
there were no significant group differences in self-reported depression changes; both groups 
showed significant, similar reductions in depressive symptoms pre- to post-assessment.
Results for IL-6 and TNF-α are consistent with other investigations examining the effects of 
MBIs on inflammatory responses. For example, significant reductions in pro-inflammatory 
cytokines have been observed in cancer patients in 8-week mindfulness courses (Carlson et 
al., 2003; Witek-Janusek et al., 2008) and sustained at a one-year follow-up (Carlson et al., 
2007). Additionally, Creswell et al. (2012) reported that compared to a wait-list control 
group, Mindfulness-Based Stress Reduction (MBSR) down-regulated pro-inflammatory 
gene expression in healthy older adults. Similarly, we observed reductions in pro-
inflammatory salivary cytokines pre-post treatment for the mindfulness group only and 
found that improvements in IL-6 were maintained after 3 months. This investigation extends 
previous findings by demonstrating similar effects (1) in a young, immunocompetent sample 
with depressive symptomatology, (2) in response to a brief mindfulness intervention, and (3) 
includes both a control group and a long-term follow-up assessment.
Mindfulness-Related Cytokine Reductions and Baseline Depressive Symptoms
In the present study, higher baseline depressive symptoms moderated the effect of 
mindfulness training; women with higher depressive symptoms at baseline showed the 
strongest cytokine reductions in response to mindfulness training. Furthermore, baseline 
levels of cytokines were not significantly correlated with baseline depressive symptoms 
(IL-6: r(59) = .22, p = .09; TNF-α: r(60) = −.053, p = .68), suggesting those with greater 
depressive symptoms did not merely have higher levels of inflammation at baseline. 
Although baseline depression did not moderate improvement in self-reported depressive 
symptoms following MBI, this finding is still consistent with recent literature showing MBIs 
may be a particularly effective treatment for those with greater baseline depressive symptom 
severity (Arch & Ayers, 2013; Greeson et al., 2015). While some evidence supports that 
MBIs are efficacious in reducing inflammatory markers (e.g., Carlson et al., 2007), a 
comprehensive review on this topic highlights that these effects are not always replicated 
(Black & Slavich, 2016), suggesting the presence of critical moderators. Baseline depression 
is predictive of impaired physiological recovery from stress (Burke, Davis, Otte, & Mohr, 
2005; Gold, Zakowski, Valdimarsdottir, & Bovbjerg, 2004), which may lead to chronic or 
excessive inflammation and ultimately increased risk for disease (Slavich & Irwin, 2014). 
Thus, baseline depression may represent an important individual difference in stress 
responding and recovery, and serve as a proxy for a variety of other person-level risk factors, 
such as early life adversity, experiential avoidance, or negative cognitive appraisals, any of 
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which would be expected to respond favorably to mindfulness practice (Barnhofer, Brennan, 
Crane, Duggan, & Williams, 2014; Brown & Jones, 2010; Williams et al., 2014). Further 
work testing these other moderators is necessary.
Mechanisms of Mindfulness Training on Inflammation
Compared to a contact control group, mindfulness training predicted greater reductions in 
salivary inflammatory cytokines. Unexpectedly, depressive symptoms did not mediate this 
relation. Therefore, it is important to consider other mediators of this treatment effect. Self-
conscious affect such as that elicited by social-evaluative threat plays a central role in 
inflammatory stress responses (e.g., Rohleder, Chen, Wolf, & Miller, 2008), suggesting that 
feelings of shame or social threat may be a potential mediator. Rumination is another likely 
candidate given it is a proximal prospective risk factor for onset of depressive episodes 
(Spasojević & Alloy, 2001) and is associated with sustained inflammatory responses 
(Zoccola, Figueroa, Rabideau, Woody, & Benencia, 2014). Though not assessed in the 
current study, self-conscious affect or rumination may be plausible mediators for the effects 
seen here and should be investigated in future studies. Such mediators may be tied to other 
person-level risk factors (e.g., baseline depression), thus providing greater insight into not 
only for whom MBIs may be particularly beneficial, but identifying how MBIs exert salutary 
health effects.
Treatment Implications
Mindfulness training may influence inflammatory immune responses that contribute to 
psychological health. The clinical significance of these findings is difficult to quantify given 
a lack of norms for salivary cytokines in healthy young women with depressive 
symptomatology. However, the present study provides some normative information in this 
population that may be used in future work. Baseline cytokines have been found to 
prospectively predict incidence and persistence of depressive symptoms (Zalli et al., 2015; 
Vogelzangs et al., 2014), even among individuals without psychiatric disorders (Wichers et 
al., 2006). The results of the present study suggest that, even if depression scores do not 
change significantly as a result of treatment, participation in MBIs may be associated with 
lower prospective physiological risk for depressive episodes. Moreover, behavioral 
interventions may represent promising alternatives for individuals with greater inflammatory 
dysregulation, who show a poorer response to antidepressant medications (Vogelzangs et al., 
2014). Finally, future work should examine the possibility that MBIs may lower risk of 
physical disorders with high depression comorbidity (e.g.,cardiovascular disease; Joynt, 
Whellan, & O'Connor, 2003) by reducing inflammation.
Limitations and Future Directions
The present study has several limitations. First, although participants were recruited for mild 
to moderate depressive symptoms (scores of 16-24 on CES-D), mean depression scores had 
fallen to 12.53 (SD: 6.25; range: 2-32) by the first session. This is likely due to some 
baseline scores being artificially elevated due to life stress. While the standard deviation and 
range reflect that some participants were still experiencing significant depressive symptoms 
at this time, others were not. Because this decrease may have limited our ability to find 
group differences on this measure, higher cut scores (Lawrence et al., 2006) or standardized 
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interviews for depression screening may be necessary. Second, generalizability is limited to 
young, primarily Caucasian, college females. However, gender bias in depression emerges in 
mid-to-late adolescence (e.g., ages 14-18) and rates of depression do not differ between 
students and non-students (Hankin et al., 1998; Rutter, Caspi, & Moffitt, 2003). While 
findings may not be generalizable to specific clinical populations, they may be generalizable 
to the population as a whole, particularly during this developmental period of heightened 
vulnerability to depression. Additional studies are needed to replicate these findings in 
populations with greater depressive symptomatology.
Third, the study measured cytokines via whole unstimulated saliva rather than blood, and 
some studies report low correlations between the two (e.g., Riis et al., 2014). Thus, salivary 
cytokines may reflect oral immune processes rather than systemic inflammation (Izawa, 
Sugaya, et al., 2013). However, salivary cytokines correlate with psychosocial factors, 
including depression (Cloak, Alicata, Ernst, & Chang, 2015; Keller, El-Sheikh, Vaughn, & 
Granger, 2010; Sjögren et al., 2006), and reliably increase during stress (Slavish, Graham-
Engeland, Smyth, & Engeland, 2015). The oral-pharyngeal cavity is a route through which 
most foreign pathogens access the body's internal tissues and cells and is therefore critical in 
immune surveillance. Local inflammatory signaling from tissues in the mouth may be 
transmitted to the brain via the trigeminal nerve (Navarro, Iyomasa, Leite-Panissi, Almeida, 
& Branco, 2006). Salivary cytokines have been shown to correlate with brain activity in 
regions strongly implicated in depression, suggesting that inflammation within the oral 
cavity may communicate with the brain and alter motivational state or emotional processing 
(O'Connor, Irwin, & Wellisch, 2009). Future research should continue to examine 
associations between salivary inflammation, systemic inflammation, and health (Slavish et 
al., 2015). Even if salivary cytokines do not reliably correspond to blood-based measures, 
salivary inflammation may still be strongly predictive of disease and well-being.
Fourth, cytokines in the contact-control group were not assessed at 3-month follow-up due 
to an ethical obligation to offer treatment to control participants following the post-treatment 
assessment. Future studies should assess both intervention and control groups at longer-term 
follow-up assessments to determine the effects of time and dose (Carmody & Baer, 2009). 
Furthermore, although the contact-control condition accounted for the influence of the 
passage of time, it did not account for the impact of expectancy, demand, social support, or 
other nonspecific factors of a group intervention.
Finally, the current study did not offer a full-length, empirically supported mindfulness 
training program, such MBSR or MBCT. These programs, which typically include 8 weekly 
2.5-hour sessions, have significant therapeutic effects (Keng et al., 2011; Chiesa & Serretti, 
2011; Piet & Hougaard, 2011). It is possible that components not offered in the current study 
are necessary for increasing awareness of emotional and cognitive processes and would have 
differentially impacted depressive symptoms.
Conclusion and Implications—The current study supports the notion that brief 
mindfulness training can have salutary effects on inflammation among relatively healthy, 
immunocompetent individuals with depressive symptomatology. Notably, pro-inflammatory 
cytokines may play a role in the development or persistence of depression (e.g, Vogelzangs 
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et al., 2014; Wichers et al., 2006). Therefore, the finding that mindfulness training is 
associated with reduced inflammation supports further investigation of the capacity of 
mindfulness training to prevent onset and relapse of depressive disorders via reduced 
inflammation. Reducing this risk factor may be a meaningful step towards depression 
prevention.
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Figure 1. 
Flowchart for participant progress (based on the consolidated standards of reporting trials 
[CONSORT] recommendations)
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Figure 2. 
Mean levels of cytokines at baseline and post-treatment assessment by condition, illustrating 
condition effect on change in cytokines pre- to post-treatment.
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Figure 3. 
Depiction of the interaction between baseline scores on the CES-D and condition predicting 
Time 2 cytokines controlling for baseline cytokines.
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Table 1
Descriptives by Condition (N = 64)
Variable Mindfulness Condition (n = 31) Contact-Control Condition (n = 33)
Age: M (SD) 19.15 (.17) 19.11 (.16)
Body Mass Index (BMI) 22.76 (3.03) 22.22 (2.72)
Grade Level: N (%)
    Freshman 22 (70%) 27 (82%)
    Sophomore 6 (20%) 3 (9%)
    Junior 3 (10%) 3 (9%)
Race: N (%)
    Caucasian 25 (81%) 30 (91%)
    African-American 4 (13%) 1 (3%)
    Asian 2 (6%) 2 (6%
Religious Affiliation: N (%)
    Christian 26 (84%) 25 (76%)
    Hindu 1 (4%) 1 (3%)
    No Religious Affiliation 2 (6%) 5 (15%)
    No Answer 2 (6%) 2 (6%)
Note. Standard Deviations and Within-group Percentages in Parentheses.
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